Programme by Day

Print this page

  Personalized Programme
The Personalized Programme enables you to compile an individual program with events and contributions of your interest. Therefore, it can be used very well to plan your actual congress visit at an early point of time. Please log on with your username and password to use the Personalized Programme.
» Login
» Create account
» Help
« previous day

Friday, 15 September 2017

next day »
No. S-09 - Symposium
Time: 08.30-10.00
Room: Plenary
Session title: Prevention of schizophrenic and other psychoses - activities for implementation in Europe
  Joachim Klosterkötter, Cologne, Germany Chairperson
  Paolo Fusar-Poli, London, United Kingdom Co-Chairperson
No. S-10 - Symposium
Time: 08.30-10.00
Room: Harvard
Session title: Formal thought disorder in schizophrenia - phenomenology and imaging correlates
  Sebastian Walther, Bern, Switzerland Chairperson
  Igor Nenadic, Marburg, Germany Co-Chairperson
No. S-11 - Symposium
Time: 08.30-10.00
Room: Stanford
Session title: Glutamatergic alterations in central nervous system disorders: a role for cognitive dysfunctions
  Francesca Calabrese, Milan, Italy Chairperson
  Judith Regina Homberg, Nijmegen, Netherlands Co-Chairperson
No. S-12 - Symposium
Time: 08.30-10.00
Room: Princeton
Session title: Autoimmune encephalitis and mild encephalitis
  Karl Bechter, Günzburg, Germany Chairperson
  Souhel Najjar, New York, USA Co-Chairperson
No. D-02 - Pro and Con Debate
Time: 10.30-12.00
Room: Plenary
Session title: Antipsychotics are not the mainstay of schizophrenia treatment under long-term conditions
  Werner Strik, Bern, Switzerland Chairperson
No. S-13 - Symposium
Time: 10.30-12.00
Room: Harvard
Session title: Delusions: from understanding causal mechanisms to deriving novel psychological interventions
  Tania Lincoln, Hamburg, Germany Chairperson
  Daniel Freeman, Oxford, United Kingdom Co-Chairperson
No. S-14 - Symposium
Time: 10.30-12.00
Room: Stanford
Session title: Glutamate dysfunction in psychosis
  Michael Sand, Ridgefield, USA Chairperson
  Philip McGuire, London, United Kingdom Co-Chairperson
No. O-03 - Oral Presentation
Time: 10.30-12.00
Room: Princeton
Session title: Drug and rTMS treatment
  Matti Isohanni, Oulu, Finland Chairperson
No. PL-02 - Plenary Lecture
Time: 12.15-13.00
Room: Plenary
Session title: Genomics and the nature of schizophrenia
  Eva Meisenzahl, Düsseldorf, Germany Chairperson
001 Genomics and the nature of schizophrenia  
  Michael J. Owen, Cardiff, United Kingdom Speaker
  Discussion (15 min)
No. P-05 - Poster Session
Time: 13.30-14.30
Room: Foyer, Ground Floor
Session title: Risk factors
  Emmanuelle Peters, London, United Kingdom Chairperson
001 Resilience and risk, mental health and well-being: how do these concepts relate?  
  Frauke Schultze-Lutter, Bern, Switzerland Speaker
002 15-year stability of transition risks to psychosis in ultra high individuals at the oasis: the hidden role of pretest risk enrichment  
  Erika Palombini, London, United Kingdom Speaker
003 Cognitive and perceptual basic symptoms in the community and their association with age  
  Frauke Schultze-Lutter, Bern, Switzerland Speaker
004 Relation between the duration of untreated psychosis (DUP) and negative symptoms  
  Regina Vila-Badia, Sant Boi de Llobregat, Spain Speaker
005 Schizotypy and childhood trauma as suicidal risk factors in a non-clinical sample  
  Krisztina Kocsis-Bogar, Vienna, Austria Speaker
006 Gender differences in childhood trauma in patients with first-episode psychosis and healthy controls: a preliminary study  
  Anna Butjosa, Sant Boi Del Llobregat, Spain Speaker
007 Association between childhood trauma and suicide risk in patients with first episode psychosis  
  Itziar Riera López de Aguileta, Barcelona, Spain Speaker
008 Effects of seizures and obstetrical traumas on individuals with schizophrenia  
  Mihail Cristian Pirlog, Bucharest, Romania Speaker
009 The effects of sleep disturbance in severe mental disorders  
  Jannicke Fjæra Laskemoen, Oslo, Norway Speaker
010 Defining depot of imagination and its role in the prevention of schizophrenia  
  Ajay Dogra, Noida, India Speaker
011 Schizophrenia is frequently not primary cerebral disorder  
  Nikola Ilankovic, Belgrade, Serbia Speaker
No. P-06 - Poster Session
Time: 13.30-14.30
Room: Event Area, Ground Floor
Session title: Psychopathology and comorbidity
  Sebastian Walther, Bern, Switzerland Chairperson
No. P-07 - Poster Session
Time: 13.30-14.30
Room: Event Area, Ground Floor
Session title: Drug and alternative treatment 2
  Johannes Schröder, Heidelberg, Germany Chairperson
001 Usefulness of paliperidone palmitate in a home treatment team in reducing symptoms and preventing hospitalization  
  David Corcoles, Barcelona, Spain Speaker
002 Conditions of use of three-month paliperidone palmitate in a Valencia sample: a naturalistic descriptive study  
  Silvia Rodriguez Portillo, Valencia, Spain Speaker
003 Clozapine in Dutch ambulatory care: prescription rates and proportions of patients with an indication for this drug  
  Yvonne van der Zalm, Leidschendam, Netherlands Speaker
004 Qualitative analysis of clozapine non-response patterns in a long-term naturalistic setting  
  Tomas Kasparek, Brno, Czech Republic Speaker
005 Antipsychotics and schizophrenia  
  Markella Fiste, Chaidari Athens, Greece Speaker
006 Psychosis and H. Pylori  
  Markella Fiste, Chaidari Athens, Greece Speaker
007 Influencing brain networks with 1 Hz rTMS treatment in patients with schizophrenia and auditory verbal hallucinations  
  Leonie Bais, Groningen, Netherlands Speaker
008 The effect of age on treatment response to tDCS in patients with schizophrenia: a meta-regression analysis  
  Tae Young Lee, Seoul, Republic of Korea Speaker
009 Reduction of apathy in schizophrenia after tDCS: a case study  
  Leonie van Asperen, Groningen, Netherlands Speaker
010 Effects of trans-cranial direct current stimulation on catatonic symptoms of schizophrenia  
  Kashani Shoaib Ahmed, Quetta Balochistan, Pakistan Speaker
011 MyPilot - an app development project to augment treatment in psychosis and bipolar disorder  
  Kristin Lie Romm, Oslo, Norway Speaker
No. P-08 - Poster Session
Time: 13.30-14.30
Room: Event Area, Ground Floor
Session title: Neuroimaging and psychophysiology
  Florian Schlagenhauf, Berlin, Germany Chairperson
001 Association between cognitive control and negative symptoms in psychosis  
  Nicky Klaasen, Groningen, Netherlands Speaker
002 Phenomenology and neurobiology of inner speech in healthy subjects and its implication in understanding of auditory verbal hallucinations  
  Eva Simkova, Klecany, Czech Republic Speaker
003 Blood perfusion in left inferior and middle frontal gyrus predicts functional capacity in schizophrenia  
  Andrea Cantisani, Bern, Switzerland Speaker
004 Deficits in context-dependent adaptive coding in early psychosis and individuals with schizotypal personality traits  
  Matthias Kirschner, Zurich, Switzerland Speaker
005 Disrupted thalamo-cortical connectivity as an endophenotype of the schizophrenia: DTI tractography study in the unaffected relatives  
  Kang Ik Cho, Seoul, Republic of Korea Speaker
006 Brain structural, electrophysiological, cognitive and clinical profiles of at-risk mental state: the longitudinal Minds in Transition (MinT) study  
  Ulrich Schall, Waratah, Australia Speaker
007 Associations between dynamic brain connectivity and reduced goal-directed behavior as indexed by measures of actigraphy and apathy  
  Michelle Servaas, Groningen, Netherlands Speaker
008 Psychophysiological responses during disgust-related stimuli in patients with schizophrenia - a preliminary report  
  Bartosz Bohaterewicz, Warsaw, Poland Speaker
009 Aberrant activity during coherent motion perception in individuals at high risk of psychosis  
  Rocio Mayol, Santiago, Chile Speaker
No. S-15 - Symposium
Time: 14.30-16.00
Room: Harvard
Session title: Deconstructing schizophrenia?
  Wolfgang Gaebel, Düsseldorf, Germany Chairperson
  Silvana Galderisi, Naples, Italy Co-Chairperson
001 Schizophrenia: deconstruction or destruction?  
  Michael J. Owen, Cardiff, United Kingdom Speaker
002 The ICD-11 approach to schizophrenia  
  Wolfgang Gaebel, Düsseldorf, Germany Speaker
003 Subtyping schizophrenia by means of negative symptoms?  
  Silvana Galderisi, Naples, Italy Speaker
004 The past and future role of pathognomonic symptoms for schizophrenia  
  Florian Schlagenhauf, Berlin, Germany Speaker
  Discussion (15 min)
No. S-16 - Symposium
Time: 14.30-16.00
Room: Stanford
Session title: Update on schizophrenia motor symptoms
  Sebastian Walther, Bern, Switzerland Chairperson
  Manuel Morrens, Antwerp, Belgium Co-Chairperson
No. S-17 - Symposium
Time: 14.30-16.00
Room: Princeton
Session title: Auditory hallucinations: converging evidence from neuroimaging
  Branislava Curcic-Blake, Groningen, Netherlands Chairperson
  Kenneth Hugdahl, Bergen, Norway Co-Chairperson
No. SA-02 - State-of-the-Art-Lecture
Time: 14.30-16.00
Room: Plenary
Session title: State-of-the-Art Lectures 2
  Joachim Klosterkötter, Cologne, Germany Chairperson
001 Prevention of psychosis – current achievements and future challenges  
  Paolo Fusar-Poli, London, United Kingdom Speaker
002 Fighting stigma - advancing recovery  
  Georg Schomerus, Greifswald, Germany Speaker
  Discussion (15 min)
No. S-18 - Symposium
Time: 16.30-18.00
Room: Plenary
Session title: Negative symptoms: research perspectives and implications for recovery
  Silvana Galderisi, Naples, Italy Chairperson
  Stefan Kaiser, Chêne-Bourg, Switzerland Co-Chairperson
No. S-19 - Symposium
Time: 16.30-18.00
Room: Harvard
Session title: Symptom dimensions in schizophrenia brain correlates and personalised treatment options
  Igor Nenadic, Marburg, Germany Chairperson
  Werner Strik, Bern, Switzerland Co-Chairperson
No. S-20 - Symposium
Time: 16.30-18.00
Room: Stanford
Session title: Altered inference about relevance in psychosis - computational approaches
  Florian Schlagenhauf, Berlin, Germany Chairperson
  André Schmidt, Basel, Switzerland Co-Chairperson
No. O-04 - Oral Presentation
Time: 16.30-18.00
Room: Princeton
Session title: Psychosocial treatment and mental health care
  Wolfgang Wölwer, Düsseldorf, Germany Chairperson
  Discussion (15 min)